

## DEXILANT SOLUTAB - (30MG ; TABLET,ORALLY DISINTEGRATING,DELAYED RELEASE)

<b>Generic Name</b>	DEXLANSOPRAZOLE	<b>Innovator</b>	Takeda
<b>Dosage</b>	30MG ; TABLET,ORALLY DISINTEGRATING,DELAYED RELEASE	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	DEXILANT SoluTab delayed-release orally disintegrating tablets (DEXILANT SoluTab) are indicated in patients 12 years of age and older for: • Maintenance of healed EE and relief of heartburn. • Treatment of symptomatic non-erosive GERD.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.